NTI Recorded Session NTI25326

Euglycemic DKA: Sweet, but Not Too Sweet

Author(s): Daniel L Arellano, PhD,RN,ACNP-BC,CCRN,CEN,CFRN,EMT-P, FCCM, FAANP

Contact Hours 1.00

CERP A 1.00

Pharmacology Hours 0.50

Expires Dec 31, 2027

Topics: Endocrine, Pharmacology

Population: Adult

Role: APRN

Start Activity
Fees
Member: Free
NonMember: $10.00
Get CE

Added to Collection

Activity Summary

Euglycemic DKA is a life-threatening emergency which is becoming more common since the introduction of SGLT-2 medications. This session explores the agents most associated with euglycemic DKA, differential diagnosis and treatment modalities for this condition. Case studies are used to enhance the learner's understanding. Pharmacology content = 50%

Objectives

  • Identify the mechanism of SGLT2 inhibitors most commonly associated with euglycemic DKA.
  • Describe the risk factors and differential diagnosis for euglycemic DKA.
  • Explain the management strategies for euglycemic DKA compared with normal DKA.

Continuing Education Disclosure Statement

Criteria for Awarding Contact Hours

Learners must complete the entire activity and the associated evaluation AND read Implicit Bias impacts patient outcomes. No partial credit will be awarded.

Accreditation

American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for {contactHours} contact hours.

Disclosures

The Nurse Planner has determined that no individuals with the ability to control content of this activity have relevant relationships with ineligible companies.

Activities with pharmacotherapeutic credit are to assist the APRN in fulfilling their education requirements for licensure and certification renewals.

Refund Policy

Continuing Education Activities are nonrefundable.